Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model
- Authors:
- Ewa Maj
- Beata Filip-Psurska
- Magdalena Milczarek
- Mateusz Psurski
- Andrzej Kutner
- Joanna Wietrzyk
-
Affiliations: Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland, Pharmaceutical Research Institute, 01-793 Warsaw, Poland - Published online on: December 15, 2017 https://doi.org/10.3892/ijo.2017.4228
- Pages: 337-366
-
Copyright: © Maj et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Adler I: Primary Malignant Growths of the Lungs and Bronchi; A Pathological and Clinical Study. Longmans; Green, New York, NY: 1912 | |
Debakey M: Carcinoma of the lung and tobacco smoking: A historical perspective. Ochsner J. 1:106–108. 1999.PubMed/NCBI | |
Proctor RN: The history of the discovery of the cigarette-lung cancer link: Evidentiary traditions, corporate denial, global toll. Tob Control. 21:87–91. 2012. View Article : Google Scholar : PubMed/NCBI | |
Dubey AK, Gupta U and Jain S: Epidemiology of lung cancer and approaches for its prediction: A systematic review and analysis. Chin J Cancer. 35:712016. View Article : Google Scholar : PubMed/NCBI | |
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gadgeel SM, Ramalingam SS and Kalemkerian GP: Treatment of lung cancer. Radiol Clin North Am. 50:961–974. 2012. View Article : Google Scholar : PubMed/NCBI | |
Feldman D, Krishnan AV, Swami S, Giovannucci E and Feldman BJ: The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 14:342–357. 2014. View Article : Google Scholar : PubMed/NCBI | |
Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, Tuckey RC and Elmets CA: Vitamin D signaling and melanoma: Role of vitamin D and its receptors in melanoma progression and management. Lab Invest. 97:706–724. 2017. View Article : Google Scholar : PubMed/NCBI | |
Higashimoto Y, Ohata M, Nishio K, Iwamoto Y, Fujimoto H, Uetani K, Suruda T, Nakamura Y, Funasako M and Saijo N: 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res. 16(5A): 2653–2659. 1996.PubMed/NCBI | |
Güzey M, Sattler C and DeLuca HF: Combinational effects of vitamin D3 and retinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 249:735–744. 1998. View Article : Google Scholar : PubMed/NCBI | |
Young MRI, Ihm J, Lozano Y, Wright MA and Prechel MM: Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother. 41:37–45. 1995.PubMed/NCBI | |
Young MRI, Lozano Y, Ihm J, Wright MA and Prechel MM: Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Cancer Lett. 104:153–161. 1996. View Article : Google Scholar : PubMed/NCBI | |
Norton R and O'Connell MA: Vitamin D: Potential in the prevention and treatment of lung cancer. Anticancer Res. 32:211–221. 2012.PubMed/NCBI | |
Mernitz H, Smith DE, Wood RJ, Russell RM and Wang XD: Inhibition of lung carcinogenesis by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in the A/J mouse model: Evidence of retinoid mitigation of vitamin D toxicity. Int J Cancer. 120:1402–1409. 2007. View Article : Google Scholar : PubMed/NCBI | |
Yudoh K, Matsuno H and Kimura T: 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med. 133:120–128. 1999. View Article : Google Scholar : PubMed/NCBI | |
Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y and Mabjeesh NJ: 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 6:1433–1439. 2007. View Article : Google Scholar : PubMed/NCBI | |
Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL and Johnson CS: Role of vitamin D receptor in the anti-proliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 69:967–975. 2009. View Article : Google Scholar : PubMed/NCBI | |
Bao BY, Yao J and Lee YF: 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis. 27:1883–1893. 2006. View Article : Google Scholar : PubMed/NCBI | |
Crino L and Metro G: Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev. 23:79–91. 2014. View Article : Google Scholar : PubMed/NCBI | |
McMahon G: VEGF receptor signaling in tumor angiogenesis. Oncologist. 5(Suppl 1): 3–10. 2000. View Article : Google Scholar : PubMed/NCBI | |
Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, Schiller J and Johnson DH: Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 5:1416–1423. 2010. View Article : Google Scholar : PubMed/NCBI | |
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI | |
Aggarwal C, Somaiah N and Simon G: Antiangiogenic agents in the management of non-small cell lung cancer: Where do we stand now and where are we headed? Cancer Biol Ther. 13:247–263. 2012. View Article : Google Scholar : PubMed/NCBI | |
Calero R, Morchon E, Johnsen JI and Serrano R: Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis. PLoS One. 9:e956282014. View Article : Google Scholar : PubMed/NCBI | |
Teodoro JG, Evans SK and Green MR: Inhibition of tumor angiogenesis by 53: A new role forthe guardian of the genome. J Mol Med (Berl). 85:1175–1186. 2007. View Article : Google Scholar | |
Wietrzyk J, Nevozhay D, Filip B, Milczarek M and Kutner A: The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res. 27(5A): 3387–3398. 2007.PubMed/NCBI | |
Wietrzyk J, Nevozhay D, Milczarek M, Filip B and Kutner A: Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother Pharmacol. 62:787–797. 2008. View Article : Google Scholar : PubMed/NCBI | |
Milczarek M, Rosinska S, Psurski M, Maciejewska M, Kutner A and Wietrzyk J: Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res. 33:433–444. 2013.PubMed/NCBI | |
Milczarek M, Psurski M, Kutner A and Wietrzyk J: Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer. 13:2942013. View Article : Google Scholar : PubMed/NCBI | |
Milczarek M, Filip-Psurska B, Swiętnicki W, Kutner A and Wietrzyk J: Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Oncol Rep. 32:491–504. 2014. View Article : Google Scholar : PubMed/NCBI | |
Maj E, Filip-Psurska B, Świtalska M, Kutner A and Wietrzyk J: Vitamin D analogs potentiate the antitumor effect of imatinib mesylate in a human A549 lung tumor model. Int J Mol Sci. 16:27191–27207. 2015. View Article : Google Scholar : PubMed/NCBI | |
Trynda J, Turlej E, Milczarek M, Pietraszek A, Chodyński M, Kutner A and Wietrzyk J: Antiproliferative activity and in vivo toxicity of double-point modified analogs of 1,25-dihydroxyergocalciferol. Int J Mol Sci. 16:24873–24894. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kieda C, Paprocka M, Krawczenko A, Załecki P, Dupuis P, Monsigny M, Radzikowski C and Duś D: New human microvascular endothelial cell lines with specific adhesion molecules phenotypes. Endothelium. 9:247–261. 2002. View Article : Google Scholar | |
Nevozhay D: Cheburator software for automatically calculating drug inhibitory concentrations from in vitro screening assays. PLoS One. 9:e1061862014. View Article : Google Scholar : PubMed/NCBI | |
McDaid HM and Johnston PG: Synergistic interaction between paclitaxel and 8-chloro-adenosine 3′,5′-monophosphate in human ovarian carcinoma cell lines. Clin Cancer Res. 5:215–220. 1999.PubMed/NCBI | |
Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI | |
Chou TC and Talalay P: Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem. 115:207–216. 1981. View Article : Google Scholar : PubMed/NCBI | |
Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI | |
Ekici OD, Li ZZ, Campbell AJ, James KE, Asgian JL, Mikolajczyk J, Salvesen GS, Ganesan R, Jelakovic S, Grütter MG, et al: Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10. J Med Chem. 49:5728–5749. 2006. View Article : Google Scholar : PubMed/NCBI | |
Ramnath N, Kim S and Christensen PJ: Vitamin D and lung cancer. Expert Rev Respir Med. 5:305–309. 2011. View Article : Google Scholar : PubMed/NCBI | |
Switalska M, Nasulewicz-Goldeman A, Opolska A, Maciejewska M, Kutner A and Wietrzyk J: The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells. Anticancer Drugs. 23:70–80. 2012. View Article : Google Scholar | |
Pan F, Tian J, Zhang X, Zhang Y and Pan Y: Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. J Cancer Res Clin Oncol. 137:1397–1408. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhuravel E, Efanova O, Shestakova T, Glushko N, Mezhuev O, Soldatkina M and Pogrebnoy P: Administration of vitamin D3 improves antimetastatic efficacy of cancer vaccine therapy of Lewis lung carcinoma. Exp Oncol. 32:33–39. 2010.PubMed/NCBI | |
Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, et al: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 26:650–656. 2008. View Article : Google Scholar : PubMed/NCBI | |
Kerbel RS, Viloria-Petit A, Klement G and Rak J: 'Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer. 36:1248–1257. 2000. View Article : Google Scholar : PubMed/NCBI | |
Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P and Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 105:R15–R24. 2000. View Article : Google Scholar : PubMed/NCBI | |
Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G and Kerbel RS: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62:2731–2735. 2002.PubMed/NCBI | |
Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R and Bjarnason G: Sunitinib therapy for metastatic renal cell carcinoma: Recommendations for management of side effects. Can Urol Assoc J. 1(Suppl): S41–S54. 2007. | |
Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F and Buonerba C: Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 59:526–540. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wietrzyk J, Pełczyńska M, Madej J, Dzimira S, Kuśnierczyk H, Kutner A, Szelejewski W and Opolski A: Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). Steroids. 69:629–635. 2004. View Article : Google Scholar : PubMed/NCBI | |
Díaz GD, Paraskeva C, Thomas MG, Binderup L and Hague A: Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res. 60:2304–2312. 2000.PubMed/NCBI | |
Pálmer HG, González-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, et al: Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 154:369–387. 2001. View Article : Google Scholar : PubMed/NCBI | |
Teng CLJ, Yu CTR, Hwang WL, Tsai JR, Liu HC, Hwang GY and Hsu SL: Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells. Ann Hematol. 92:301–313. 2013. View Article : Google Scholar | |
Nishikawa M, Miyake H and Fujisawa M: Enhanced sensitivity to sunitinib by inhibition of Akt1 expression in human castration-resistant prostate cancer C3 cells both in vitro and in vivo. Urology. 85:1215.e1–1215.e7. 2015. View Article : Google Scholar | |
Uzu M, Sato H, Yamada R, Kashiba T, Shibata Y, Yamaura K and Ueno K: Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells. J Pharmacol Sci. 128:17–26. 2015. View Article : Google Scholar : PubMed/NCBI | |
Stepień A, Izdebska M and Grzanka A: The types of cell death. Postepy Hig Med Dosw (Online). 61:420–428. 2007.In Polish. | |
Korwek Z and Alster O: The role of the DNA damage response in apoptosis and cell senescence. Postepy Biochem. 60:248–262. 2014.In Polish. | |
Koren R, Wacksberg S, Weitsman GE and Ravid A: Calcitriol sensitizes colon cancer cells to H2O2-induced cytotoxicity while inhibiting caspase activation. J Steroid Biochem Mol Biol. 101:151–160. 2006. View Article : Google Scholar : PubMed/NCBI | |
Diker-Cohen T, Koren R, Liberman UA and Ravid A: Vitamin D protects keratinocytes from apoptosis induced by osmotic shock, oxidative stress, and tumor necrosis factor. Ann N Y Acad Sci. 1010:350–353. 2003. View Article : Google Scholar | |
Lavallard VJ, Pradelli LA, Paul A, Bénéteau M, Jacquel A, Auberger P and Ricci JE: Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells. Cancer Res. 69:3013–3020. 2009. View Article : Google Scholar : PubMed/NCBI | |
Costa PM, Cardoso AL, Nóbrega C, Pereira de Almeida LF, Bruce JN, Canoll P and Pedroso de Lima MC: MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. Hum Mol Genet. 22:904–918. 2013. View Article : Google Scholar : | |
Liu ZL, Wang H, Liu J and Wang ZX: MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar | |
Xu L, Huang Y, Chen D, He J, Zhu W, Zhang Y and Liu X: Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer. Cancer Genet. 207:214–220. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhang YX, Yue Z, Wang PY, Li YJ, Xin JX, Pang M, Zheng QY and Xie SY: Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth. Biomed Pharmacother. 67:97–102. 2013. View Article : Google Scholar : PubMed/NCBI | |
Vakifahmetoglu H, Olsson M and Zhivotovsky B: Death through a tragedy: Mitotic catastrophe. Cell Death Differ. 15:1153–1162. 2008. View Article : Google Scholar : PubMed/NCBI | |
Kim SH, Chen G, King AN, Jeon CK, Christensen PJ, Zhao L, Simpson RU, Thomas DG, Giordano TJ, Brenner DE, et al: Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer. 77:265–271. 2012. View Article : Google Scholar : PubMed/NCBI | |
Naves M, Alvarez-Hernández D, Fernández-Martín JL, Paz-Jiménez J, García-Prado P, Fernández-Coto T, Santamaría I and Cannata-Andía J: Effect of VDR gene polymorphisms on osteocalcin secretion in calcitriol-stimulated human osteoblasts. Kidney Int Suppl. 63:S23–S27. 2003. View Article : Google Scholar | |
Alvarez-Hernandez D, Naves-Diaz M, Gomez-Alonso C, Coto E and Cannata-Andia JB: Tissue-specific effect of VDR gene polymorphisms on the response to calcitriol. J Nephrol. 21:843–849. 2008.PubMed/NCBI | |
Dogan I, Onen HI, Yurdakul AS, Konac E, Ozturk C, Varol A and Ekmekci A: Polymorphisms in the vitamin D receptor gene and risk of lung cancer. Med Sci Monit. 15:BR232–BR242. 2009.PubMed/NCBI | |
Fu Y, Li J and Zhang Y: Polymorphisms in the vitamin D receptor gene and the lung cancer risk. Tumour Biol. 35:1323–1330. 2014. View Article : Google Scholar | |
Wu X, Cheng J and Yang K: Vitamin D-related gene polymorphisms, plasma 25-hydroxy-vitamin D, cigarette smoke and non-small cell lung cancer (NSCLC) risk. Int J Mol Sci. 17:202016. View Article : Google Scholar | |
Vaughan-Shaw PG, O'Sullivan F, Farrington SM, Theodoratou E, Campbell H, Dunlop MG and Zgaga L: The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: Systematic review and meta-analysis. Br J Cancer. 116:1092–1110. 2017. View Article : Google Scholar : PubMed/NCBI | |
Slominski AT, Kim TK, Takeda Y, Janjetovic Z, Brozyna AA, Skobowiat C, Wang J, Postlethwaite A, Li W, Tuckey RC, et al: RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D. FASEB J. 28:2775–2789. 2014. View Article : Google Scholar : PubMed/NCBI | |
Brożyna AA, Jóźwicki W, Skobowiat C, Jetten A and Slominski AT: RORα and RORγ expression inversely correlates with human melanoma progression. Oncotarget. 7:63261–63282. 2016. View Article : Google Scholar | |
Slominski AT, Kim TK, Hobrath JV, Oak ASW, Tang EKY, Tieu EW, Li W, Tuckey RC and Jetten AM: Endogenously produced nonclassical vitamin D hydroxy-metabolites act as 'biased' agonists on VDR and inverse agonists on RORα and RORγ. J Steroid Biochem Mol Biol. 173:42–56. 2017. View Article : Google Scholar | |
Du J and Xu R: RORα, a potential tumor suppressor and therapeutic target of breast cancer. Int J Mol Sci. 13:15755–15766. 2012. View Article : Google Scholar | |
Slominski AT, Kim TK, Shehabi HZ, Semak I, Tang EKY, Nguyen MN, Benson HAE, Korik E, Janjetovic Z, Chen J, et al: In vivo evidence for a novel pathway of vitamin D-3 metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 26:3901–3915. 2012. View Article : Google Scholar : PubMed/NCBI | |
Slominski AT, Kim TK, Shehabi HZ, Tang EKY, Benson HAE, Semak I, Lin Z, Yates CR, Wang J, Li W, et al: In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland. Mol Cell Endocrinol. 383:181–192. 2014. View Article : Google Scholar : PubMed/NCBI | |
Slominski AT, Kim TK, Li W, Postlethwaite A, Tieu EW, Tang EKY and Tuckey RC: Detection of novel CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland. Sci Rep. 5:148752015. View Article : Google Scholar : PubMed/NCBI | |
Slominski AT, Kim TK, Li W and Tuckey RC: Classical and non-classical metabolic transformation of vitamin D in dermal fibroblasts. Exp Dermatol. 25:231–232. 2016. View Article : Google Scholar : | |
Zhang Q, Kanterewicz B, Shoemaker S, Hu Q, Liu S, Atwood K and Hershberger P: Differential response to 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations. J Steroid Biochem Mol Biol. 136:264–270. 2013. View Article : Google Scholar | |
Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M, Inoue H and Mori M: Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol. 15:236–241. 2004. View Article : Google Scholar : PubMed/NCBI | |
Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G and Kállay E: The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem. 58:277–285. 2010. View Article : Google Scholar : | |
Luo W, Hershberger PA, Trump DL and Johnson CS: 24-Hydroxylase in cancer: Impact on vitamin D-based anticancer therapeutics. J Steroid Biochem Mol Biol. 136:252–257. 2013. View Article : Google Scholar : | |
Zhang Q, Kanterewicz B, Buch S, Petkovich M, Parise R, Beumer J, Lin Y, Diergaarde B and Hershberger PA: CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Mol Cell Endocrinol. 355:153–161. 2012. View Article : Google Scholar : PubMed/NCBI | |
Chung I, Yu WD, Karpf AR, Flynn G, Bernardi RJ, Modzelewski RA, Johnson CS and Trump DL: Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironments. J Steroid Biochem Mol Biol. 103:768–770. 2007. View Article : Google Scholar : PubMed/NCBI | |
Spyridopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, Isner JM and Losordo DW: Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: Balance between growth and death signals. J Mol Cell Cardiol. 29:1321–1330. 1997. View Article : Google Scholar : PubMed/NCBI | |
Aonuma M, Iwahana M, Nakayama Y, Hirotani K, Hattori C, Murakami K, Shibuya M and Tanaka NG: Tumorigenicity depends on angiogenic potential of tumor cells: Dominant role of vascular endothelial growth factor and/or fibroblast growth factors produced by tumor cells. Angiogenesis. 2:57–66. 1998. View Article : Google Scholar | |
Kieser A, Weich HA, Brandner G, Marmé D and Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 9:963–969. 1994.PubMed/NCBI | |
Mukhopadhyay D, Tsiokas L and Sukhatme VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55:6161–6165. 1995.PubMed/NCBI | |
Niklińska W, Burzykowski T, Chyczewski L and Nikliński J: Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): Association with p53 gene mutation and prognosis. Lung Cancer. 34(Suppl 2): S59–S64. 2001. View Article : Google Scholar | |
Fontanini G, Boldrini L, Vignati S, Chinè S, Basolo F, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G: Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer. 34:718–723. 1998. View Article : Google Scholar : PubMed/NCBI | |
Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC and Yang PC: Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol. 20:900–910. 2002.PubMed/NCBI | |
Brown CJ, Lain S, Verma CS, Fersht AR and Lane DP: Awakening guardian angels: Drugging the p53 pathway. Nat Rev Cancer. 9:862–873. 2009. View Article : Google Scholar : PubMed/NCBI | |
Sundaram P, Dang CV and Thomas-Tikhonenko A: Myc and control of tumor neovascularization. Cancer Genome and Tumor Microenvironment. Thomas-Tikhonenko A: Springer; New York, NY: pp. 167–187. 2010, View Article : Google Scholar | |
Mahalingam D, Espitia CM, Medina EC, Esquivel JA II, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, et al: Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. Br J Cancer. 105:1563–1573. 2011. View Article : Google Scholar : PubMed/NCBI | |
Xie C, Pan Y, Hao F, Gao Y, Liu Z, Zhang X, Xie L, Jiang G, Li Q and Wang E: C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells. APMIS. 122:1251–1258. 2014. View Article : Google Scholar : PubMed/NCBI | |
O'Brate A and Giannakakou P: The importance of p53 location: Nuclear or cytoplasmic zip code? Drug Resist Updat. 6:313–322. 2003. View Article : Google Scholar | |
Levine AJ and Oren M: The first 30 years of p53: Growing ever more complex. Nat Rev Cancer. 9:749–758. 2009. View Article : Google Scholar : PubMed/NCBI | |
Patel S and Player MR: Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs. 17:1865–1882. 2008. View Article : Google Scholar : PubMed/NCBI | |
Panka DJ, Liu Q, Geissler AK and Mier JW: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. Mol Cancer. 12:172013. View Article : Google Scholar | |
Gan L, Wang J, Xu H and Yang X: Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate. 71:1158–1166. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kumagai T, O'Kelly J, Said JW and Koeffler HP: Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: Antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst. 95:896–905. 2003. View Article : Google Scholar : PubMed/NCBI | |
Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A, Takahashi H, Wakasugi T and Takeyama H: PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem. 331:161–171. 2009. View Article : Google Scholar : PubMed/NCBI | |
Clarke JM and Hurwitz HI: Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol. 4:253–263. 2013.PubMed/NCBI | |
Giuliano S and Pagès G: Mechanisms of resistance to anti-angiogenesis therapies. Biochimie. 95:1110–1119. 2013. View Article : Google Scholar : PubMed/NCBI | |
Joosten SC, Hamming L, Soetekouw PM, Aarts MJ, Veeck J, van Engeland M and Tjan-Heijnen VC: Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta. 1855:1–16. 2015. | |
Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA and Teh BT: Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70:1063–1071. 2010. View Article : Google Scholar : PubMed/NCBI | |
Wysoczynski M, Shin DM, Kucia M and Ratajczak MZ: Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: Therapeutic implications. Int J Cancer. 126:371–381. 2010. View Article : Google Scholar | |
Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013. View Article : Google Scholar | |
Chen W, Li Z, Bai L and Lin Y: NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed). 16:1172–1185. 2011. View Article : Google Scholar | |
Sanchez A, Tripathy D, Yin X, Luo J, Martinez JM and Grammas P: Sunitinib enhances neuronal survival in vitro via NF-κB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase. J Neuroinflammation. 10:932013. View Article : Google Scholar | |
Barkett M and Gilmore TD: Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene. 18:6910–6924. 1999. View Article : Google Scholar : PubMed/NCBI | |
Aoki M, Nata T, Morishita R, Matsushita H, Nakagami H, Yamamoto K, Yamazaki K, Nakabayashi M, Ogihara T and Kaneda Y: Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: Antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension. 38:48–55. 2001. View Article : Google Scholar : PubMed/NCBI | |
Royds JA, Dower SK, Qwarnstrom EE and Lewis CE: Response of tumour cells to hypoxia: Role of p53 and NFkB. Mol Pathol. 51:55–61. 1998. View Article : Google Scholar : PubMed/NCBI | |
Perkins ND and Gilmore TD: Good cop, bad cop: The different faces of NF-kappaB. Cell Death Differ. 13:759–772. 2006. View Article : Google Scholar : PubMed/NCBI | |
Krishnan AV and Feldman D: Molecular pathways mediating the anti-inflammatory effects of calcitriol: Implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer. 17:R19–R38. 2010. View Article : Google Scholar |